156 related articles for article (PubMed ID: 38086808)
1. Carmofur prevents cell cycle progression by reducing E2F8 transcription in temozolomide-resistant glioblastoma cells.
Hawkins CC; Jones AB; Gordon ER; Harsh Y; Ziebro JK; Willey CD; Griguer C; Crossman DK; Cooper SJ; Ramanadham S; Doan N; Hjelmeland AB
Cell Death Discov; 2023 Dec; 9(1):451. PubMed ID: 38086808
[TBL] [Abstract][Full Text] [Related]
2. Targeting Acid Ceramidase Inhibits Glioblastoma Cell Migration through Decreased AKT Signaling.
Hawkins CC; Jones AB; Gordon ER; Williford SE; Harsh Y; Ziebro JK; Landis CJ; Gc S; Crossman DK; Cooper SJ; Ramanadham S; Doan N; Hjelmeland AB
Cells; 2022 Jun; 11(12):. PubMed ID: 35741006
[TBL] [Abstract][Full Text] [Related]
3. Sphingolipid Metabolism in Glioblastoma and Metastatic Brain Tumors: A Review of Sphingomyelinases and Sphingosine-1-Phosphate.
Hawkins CC; Ali T; Ramanadham S; Hjelmeland AB
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32977496
[TBL] [Abstract][Full Text] [Related]
4. A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
Noack J; Choi J; Richter K; Kopp-Schneider A; Régnier-Vigouroux A
Cell Death Dis; 2014 Sep; 5(9):e1425. PubMed ID: 25255218
[TBL] [Abstract][Full Text] [Related]
5. Extracellular Sphingosine-1-Phosphate Downstream of EGFR Increases Human Glioblastoma Cell Survival.
Bassi R; Brambilla S; Tringali C; Giussani P
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201962
[TBL] [Abstract][Full Text] [Related]
6. Acid ceramidase confers radioresistance to glioblastoma cells.
Doan NB; Nguyen HS; Al-Gizawiy MM; Mueller WM; Sabbadini RA; Rand SD; Connelly JM; Chitambar CR; Schmainda KM; Mirza SP
Oncol Rep; 2017 Oct; 38(4):1932-1940. PubMed ID: 28765947
[TBL] [Abstract][Full Text] [Related]
7. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
8. Role of Luteolin as Potential New Therapeutic Option for Patients with Glioblastoma through Regulation of Sphingolipid Rheostat.
Navone SE; Guarnaccia L; Rizzaro MD; Begani L; Barilla E; Alotta G; Garzia E; Caroli M; Ampollini A; Violetti A; Gervasi N; Campanella R; Riboni L; Locatelli M; Marfia G
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203299
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Oancea-Castillo LR; Klein C; Abdollahi A; Weber KJ; Régnier-Vigouroux A; Dokic I
Cancer Biol Ther; 2017 Jun; 18(6):400-406. PubMed ID: 28494176
[TBL] [Abstract][Full Text] [Related]
10. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.
Ling Z; Zhang J; Liu Q
Bioengineered; 2022 Mar; 13(3):6012-6023. PubMed ID: 35191808
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response.
Sordillo LA; Sordillo PP; Helson L
Anticancer Res; 2016 May; 36(5):2085-95. PubMed ID: 27127108
[TBL] [Abstract][Full Text] [Related]
13. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
Bektas M; Johnson SP; Poe WE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1053-8. PubMed ID: 19597728
[TBL] [Abstract][Full Text] [Related]
14. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
15. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
16. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
17. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation.
Tsai YT; Lo WL; Chen PY; Ko CY; Chuang JY; Kao TJ; Yang WB; Chang KY; Hung CY; Kikkawa U; Chang WC; Hsu TI
J Biomed Sci; 2022 Mar; 29(1):21. PubMed ID: 35337344
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
[TBL] [Abstract][Full Text] [Related]
20. RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).
Xu J; Song J; Xiao M; Wang C; Zhang Q; Yuan X; Tian S
Bioengineered; 2021 Dec; 12(2):11768-11781. PubMed ID: 34895074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
